Announcements
- Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
- Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
- Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
- Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
More ▼
Key statistics
On Friday, Vivoryon Therapeutics NV (05Y:DEU) closed at 2.50, 525.00% above the 52 week low of 0.40 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 2.85 |
Low | 1.86 |
Bid | 2.47 |
Offer | 2.50 |
Previous close | 1.97 |
Average volume | 590.28k |
---|---|
Shares outstanding | 26.07m |
Free float | 17.35m |
P/E (TTM) | -- |
Market cap | 62.43m EUR |
EPS (TTM) | -1.13 EUR |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼